RA CAPITAL MANAGEMENT, L.P.

Registered adviser

CIK

1346824

Location

BOSTON, MA

Portfolio Value

Large $11,507,518,878

Diversification

Diversified

Filing Date

Global Rank

#494 / 8,825 ▲ 6

Top Industry

Biotechnology 97.6%

Period ended 4 months ago

Filed Aug 14, 2026 · 3mo

26 quarters · since Mar 2020

Regulatory profile

From Form ADV, the SEC filer profile, 13D/13G type codes and N-CEN, never from the name.

Holder type

Registered adviser

Form ADV roster, Nov 1, 2026

Form ADV adviser

CRD 160174

Roster of Nov 1, 2026

Regulatory AUM

$16,401,931,385

Main clients

Pooled investment vehicles (100% of AUM)

Private funds

6 funds · Venture capital funds

Focus by fund count, roster of Nov 1, 2026

$16,339,781,064 gross assets

LEI

549300ZV6X2KFAD7UG21

Private funds on Schedule D 7.B.(1)

As filed Mar 29, 2024; SEC's bulk Form ADV archive ends with 2024 filings.

$11,227,234,426 gross assets in 5 funds Hedge funds $9,377,168,016 (1) Venture capital funds $1,850,066,410 (4)

Form ADV history

Monthly rosters from Dec 2019; each row is a run with the same figures, newest first.

Rosters	Regulatory AUM	Main clients
Apr 2026 to Nov 2026	$16,401,931,385	Pooled investment vehicles (100%)
Dec 2025 to Mar 2026	$12,629,842,282	Pooled investment vehicles (99%)
Apr 2025 to Sep 2025	$12,629,842,282	Pooled investment vehicles (99%)
Apr 2024 to Mar 2025	$11,323,065,361	Pooled investment vehicles (99%)
Dec 2023 to Mar 2024	$9,650,336,033	Pooled investment vehicles (99%)
May 2023 to Nov 2023	$9,650,336,033	Pooled investment vehicles (99%)

6 earlier changes not shown.

Schedule 13D/13G stakes

Stakes of 5% or more disclosed on Schedule 13D or 13G, each on the filer's latest filing for the security. These are event-dated stakes, not the quarter-end 13F portfolio below.

Company	Schedule	Event date	Filed	Shares	% of class	Change	Status
ALEC Alector, Inc.	13G	Oct 19, 2026	9d	7,500,000	5.1%	+7,500,000 since Jun 30, 2025	Current
CRBP Corbus Pharmaceuticals Holdings, Inc.	13G	Sep 23, 2026	35d	1,914,788	9.9%	+1,484,606 since Feb 2, 2024	Current
SION Sionna Therapeutics, Inc.	13D/A not restated by this amendment, the earlier 13D's purpose stands	Sep 17, 2026	44d	6,476,193	14.3%	-3,595,519 since Nov 5, 2025	Current
BETRF BetterLife Pharma Inc.	13G	Sep 15, 2026	43d	55,420,000	9%	—	Current
TYRA Tyra Biosciences, Inc.	13D/A not restated by this amendment, the earlier 13D's purpose stands	Sep 15, 2026	48d	14,130,492	19.9%	+1,863,917 since Mar 4, 2026	Current
JTTT JATT III Acquisition Corp	13G	Aug 27, 2026	2mo	450,000	5.1%	—	Current
GHRS GH Research PLC	13G/A	Aug 12, 2026	3mo	4,897,182	7.1%	-2,779,515 since Jun 30, 2025	Current
SEPN Septerna, Inc.	13D/A not restated by this amendment, the earlier 13D's purpose stands	Aug 12, 2026	3mo	5,525,324	11.8%	—	Current
LTGO Latigo Biotherapeutics, Inc.	13G	Aug 10, 2026	3mo	5,295,690	8.4%	—	Current
WVE Wave Life Sciences, Inc.	13D/A Strategic alternatives, Other	Aug 7, 2026	3mo	34,314,406	16.8%	+88,900 since Apr 15, 2026	Current
SABS SAB Biotherapeutics, Inc.	13D/A not restated by this amendment, the earlier 13D's purpose stands	Aug 6, 2026	3mo	9,609,852	9.9%	+2,298,627 since Mar 19, 2026	Current
TCGX TCGX Acquisition Corp.	13G	Aug 6, 2026	3mo	500,000	5.5%	—	Current
OBX Obsidian Therapeutics, Inc.	13G	Aug 3, 2026	3mo	5,957,103	9.7%	—	Current
INO Inovio Pharmaceuticals, Inc.	13G	Jul 31, 2026	3mo	10,666,523	9.9%	—	Current
DBVT DBV Technologies S.A.	13G	Jul 30, 2026	3mo	18,288,220	5.8%	—	Current
IKT Inhibikase Therapeutics, Inc.	13G/A	Jul 29, 2026	3mo	14,653,994	9.9%	-10,346,006 since Jul 10, 2026	Current
CAPR Capricor Therapeutics, Inc.	13G	Jul 27, 2026	3mo	3,014,183	5.2%	—	Current
SCTX Scribe Therapeutics, Inc.	13G	Jul 27, 2026	3mo	1,802,178	9.6%	—	Current
ARTV Artiva Biotherapeutics, Inc.	13D/A not restated by this amendment, the earlier 13D's purpose stands	Jul 22, 2026	3mo	18,415,956	37.9%	+604,333 since Jun 11, 2026	Current
FRNM Freenome, Inc.	13D/A Passive investment	Jul 20, 2026	4mo	15,367,270	14.3%	+14,617,270 since Dec 5, 2025	Current
VOR Vor Biopharma Inc.	13D/A none of the classified purposes	Jul 16, 2026	4mo	12,937,855	19.9%	+41,336 since Apr 20, 2026	Current
AGEN Agenus Inc	13G	Jul 13, 2026	4mo	4,344,772	9.9%	—	Current
CLYM Climb Bio, Inc.	13D/A Control or board seats	Jul 2, 2026	4mo	23,249,186	33%	+617,785 since Apr 27, 2026	Current
ACET Adicet Bio, Inc.	13G/A	Jun 30, 2026	3mo	935,486	9.9%	-247,138 since Feb 17, 2026	Current
ACRS Aclaris Therapeutics, Inc.	13G/A	Jun 30, 2026	3mo	12,723,026	9.1%	+5,096,321 since Mar 31, 2026	Current
AVTX Avalo Therapeutics, Inc.	13G/A	Jun 30, 2026	3mo	3,483,099	6.3%	+1,027,444 since Mar 31, 2026	Current
BCRX Biocryst Pharmaceuticals Inc	13G/A	Jun 30, 2026	3mo	15,827,186	6.2%	+525,000 since Nov 4, 2025	Current
CCCC C4 Therapeutics, Inc.	13G/A	Jun 30, 2026	3mo	11,383,696	9.9%	+1,942,440 since Oct 17, 2025	Current
CRVO CervoMed Inc.	13G/A	Jun 30, 2026	3mo	1,266,143	8.6%	+239,206 since Jun 30, 2025	Current
EWTX Edgewise Therapeutics, Inc.	13G/A	Jun 30, 2026	3mo	8,392,730	7.8%	-2,035,707 since Sep 30, 2025	Current
GERN Geron Corp	13G/A	Jun 30, 2026	3mo	66,502,728	9.9%	+2,514,622 since Mar 31, 2025	Current
KPTI Karyopharm Therapeutics Inc.	13G/A	Jun 30, 2026	3mo	2,302,504	9.9%	+223,591 since Mar 26, 2026	Current
OVID Ovid Therapeutics Inc.	13G/A	Jun 30, 2026	3mo	19,549,271	9.9%	+6,289,536 since Dec 11, 2025	Current
RANI Rani Therapeutics Holdings, Inc.	13G/A	Jun 30, 2026	3mo	11,530,414	9.9%	+1,647,937 since Oct 23, 2025	Current
TSHA Taysha Gene Therapies, Inc.	13G/A	Jun 30, 2026	3mo	32,886,242	9.9%	+5,223,761 since Sep 30, 2025	Current
SLDB Solid Biosciences Inc.	13D/A not restated by this amendment, the earlier 13D's purpose stands	Jun 22, 2026	4mo	12,036,126	11.9%	+2,722,370 since Mar 13, 2026	Current
PBLS Parabilis Medicines, Inc.	13D Passive investment	Jun 11, 2026	5mo	28,933,371	23.8%	—	Current
QTTB Q32 Bio Inc.	13G	May 28, 2026	5mo	2,332,457	9.8%	—	Current
EDIT Editas Medicine, Inc.	13G	May 27, 2026	5mo	8,889,000	5.8%	—	Current
SANA Sana Biotechnology, Inc.	13G	May 14, 2026	6mo	18,750,000	6.3%	—	Current
COAG Hemab Therapeutics Holdings, Inc.	13G	May 4, 2026	6mo	7,729,773	16.6%	—	Current
ALT Altimmune, Inc.	13G	Apr 24, 2026	6mo	13,000,000	6.5%	—	Current
ACRV Acrivon Therapeutics, Inc.	13D/A not restated by this amendment, the earlier 13D's purpose stands	Apr 22, 2026	6mo	12,284,906	28.8%	+3,888,888 since Mar 19, 2026	Current
PRLD Prelude Therapeutics Inc	13G	Apr 21, 2026	6mo	6,477,309	9.9%	—	Current
JATT JATT II Acquisition Corp.	13G	Apr 20, 2026	6mo	500,000	6.4%	—	Current
FDMT 4D Molecular Therapeutics, Inc.	13G/A	Mar 31, 2026	6mo	5,105,622	9.9%	-608,230 since Dec 31, 2025	Current
IVVD Invivyd, Inc.	13G/A	Mar 31, 2026	6mo	21,342,442	7%	-7,514,766 since Dec 31, 2025	Current
OKUR OnKure Therapeutics, Inc.	13G	Mar 31, 2026	7mo	4,038,715	9.9%	—	Current
PALI Palisade Bio, Inc.	13G/A	Mar 31, 2026	6mo	17,620,479	9.9%	+1,873,650 since Dec 31, 2025	Current
PCVX Vaxcyte, Inc.	13G/A	Mar 31, 2026	6mo	12,974,599	8.9%	+10,108 since Mar 31, 2025	Current

Showing the 50 newest of 80 stakes. The REST API and the MCP server page through them all.

A 13D or 13G stays in force until its filer amends it and no amendment is due without a material change, so a stake with no filing in 24 months reads unconfirmed, never sold. An amendment reporting under 5% ends the filer's duty to amend, not necessarily the holding. Shares are restated onto today's split basis. Show 54 exited, below-5% or retired stakes

Portfolio style

Measured from the filed 13F common-share book for Jun 30, 2026, never from the firm's own description.

Style

Concentrated

The top 10 positions are 60.5% of the book (60%+)

Turnover

Medium turnover

36.1% over the last four quarters (30% to under 100%)

Horizon

Long horizon

Value-weighted holding period 14.7 quarters (12+), a floor since 32.7% of the book was already held when coverage starts

Closest benchmark: the Russell 2000 as of 2026-06-30, active share 97.5%; sector active share 90.7% against the combined 13F book's sector weights.

Over time 26 measured quarters

How the bands are measured

Style bands measure the filed 13F common-share book each closed quarter, tested in this order. Unknown: under $10,000,000 of valued equity or 5 stocks. Index-like (100+ stocks): active share of 20% or less against the closest benchmark, which is the S&P 500, S&P MidCap 400, S&P SmallCap 600, Russell 1000, Russell 2000, Nasdaq-100 or Dow Jones Industrial Average (weighted by an index-tracking fund's reported holdings or the index's constituents nearest the quarter end, over the names resolved to companies, and only when those are 90%+ of its weight) or every 13F filer's combined book, or index series holding 80%+ of the registered fund assets it advises (N-CEN) and equal to 50%+ of its book. Systematic-like: 500+ stocks, 100%+ annual turnover and a top 10 weight of 25% or less. Concentrated: a top 10 weight of 60%+ or 12 or fewer effective positions. Diversified active: none of these. Turnover is the smaller of buys and sells over average equity value, summed over four quarters: low under 30%, high 100%+. Horizon is the value-weighted number of quarters each position has been held: short under 4, long 12+.

Clone Performance

Build a hypothetical price-return history from this filer's public 13F holdings.

View clone backtest

Portfolio Concentration

84 tracked positions · as of Jun 30, 2026 · Δ vs Mar 31, 2026

Top Position

23.8%

−1.1 pts

Top 5

46.7%

−0.6 pts

Top 10

60.5%

−0.9 pts

HHI

784

Diversified−47

Portfolio Trend

26 quarters · across all stocks

Sector Breakdown

As of Jun 30, 2026

Sector	% Portfolio	Value	Positions
Healthcare	99.8%	$11,484,728,878	81
Financial Services	0.2%	$22,790,000	3

Last Quarter's Activity

Export CSV

Jun 30, 2026 vs Mar 31, 2026

Added To

Positions the filer increased

10 positions

Ticker	Company	Δ Shares	Shares	Value
ARTV	Artiva Biotherapeutics, Inc.	+8,102,340	17,955,642	$174,169,727
ACRS	Aclaris Therapeutics, Inc.	+5,918,954	12,723,026	$67,304,807
ACRV	Acrivon Therapeutics, Inc.	+3,888,888	12,229,396	$21,768,324
SLDB	Solid Biosciences Inc.	+2,696,148	12,036,126	$120,240,898
XNCR	Xencor Inc	+377,037	5,274,274	$84,915,811
AVTX	Avalo Therapeutics, Inc.	+337,032	1,000,000	$18,480,000
RZLT	Rezolute, Inc.	+265,039	9,445,039	$49,114,202
ZLAB	Zai Lab Ltd	+36,271	5,743,533	$109,127,127
BIOA	BioAge Labs, Inc.	+21,000	1,671,648	$40,972,092
DMRA	Damora Therapeutics, Inc.	+392	2,399,702	$62,416,249
No positions match the current search.

Trimmed

Positions the filer reduced

10 positions

Ticker	Company	Δ Shares	Shares	Value
GERN	Geron Corp	−20,961,615	42,809,751	$54,796,481
HOWL	Werewolf Therapeutics, Inc.	−4,293,563	2,387,744	$859,587
VOR	Vor Biopharma Inc.	−3,002,903	2,402,095	$44,222,568
EWTX	Edgewise Therapeutics, Inc.	−2,035,707	8,392,730	$340,996,619
—		−1,287,689	1,246,456	$153,937,316
ACET	Adicet Bio, Inc.	−250,000	932,624	$8,057,871
OVID	Ovid Therapeutics Inc.	−213,032	10,500,968	$28,247,603
AKTS	Aktis Oncology, Inc.	−188,679	1,314,405	$42,363,273
GHRS	GH Research PLC	−39,884	7,636,813	$205,277,533
PTN	Palatin Technologies Inc	−7,876	62,124	$670,317
No positions match the current search.

New Positions

Positions the filer opened this quarter

16 positions

Ticker	Company	Shares	Value
PBLS	Parabilis Medicines, Inc.	28,933,371	$791,906,364
COAG	Hemab Therapeutics Holdings, Inc.	7,808,627	$286,810,869
ABVX	Abivax S.A.	1,132,557	$150,924,545
ORKA	Oruka Therapeutics, Inc.	1,554,597	$147,950,996
NTLA	Intellia Therapeutics, Inc.	4,526,926	$76,595,587
DFTX	Definium Therapeutics, Inc.	1,500,000	$70,560,000
SANA	Sana Biotechnology, Inc.	18,750,000	$65,437,500
PRLD	Prelude Therapeutics Inc	6,475,882	$34,516,451
QTTB	Q32 Bio Inc.	2,332,457	$29,715,502
EDIT	Editas Medicine, Inc.	8,889,000	$28,800,360
ALT	Altimmune, Inc.	6,500,000	$19,760,000
FTH	Faeth Therapeutics, Inc.	722,020	$18,050,500
AURA	Aura Biosciences, Inc.	2,500,000	$17,750,000
SPTX	Seaport Therapeutics, Inc.	700,000	$15,204,000
JATT	JATT II Acquisition Corp.	500,000	$5,680,000
AMAN	Amanat Acquisition Corp.	375,000	$3,810,000
No positions match the current search.

Sold Out

Positions the filer fully exited

17 positions

Ticker	Company	Shares	Value
DNTH	Dianthus Therapeutics, Inc.	2,611,733	$219,176,633
PRAX	Praxis Precision Medicines, Inc.	373,787	$120,430,433
SRPT	Sarepta Therapeutics, Inc.	3,902,596	$84,920,488
SYRE	Spyre Therapeutics, Inc.	1,621,620	$81,794,512
FULC	Fulcrum Therapeutics, Inc.	6,053,960	$46,433,873
OLMA	Olema Pharmaceuticals, Inc.	2,600,000	$38,766,000
DSGN	Design Therapeutics, Inc.	2,972,973	$31,632,432
TVTX	Travere Therapeutics, Inc.	746,841	$22,188,646
GRAL	GRAIL, Inc.	428,266	$22,132,786
RLMD	Relmada Therapeutics, Inc.	2,947,369	$20,513,688
STRO	Sutro Biopharma, Inc.	715,307	$17,818,297
CTNM	Contineum Therapeutics, Inc.	1,296,012	$16,925,916
INSP	Inspire Medical Systems, Inc.	325,663	$16,797,697
HNGE	Hinge Health, Inc.	364,613	$14,059,477
WGS	GeneDx Holdings Corp.	209,887	$13,478,943
RNA	Atrium Therapeutics, Inc.	864,102	$11,553,043
MPLT	MapLight Therapeutics, Inc.	248,294	$5,047,817
No positions match the current search.

Portfolio Positions

Compact Export CSV View 13F filing

84 tracked positions · $11,507,518,878 total · filing declares 85 positions · $11,507,522,068 · as of Jun 30, 2026

All sectors Financial Services Healthcare

Showing 1–50 of 84 positions by value · page 1 of 2

Ticker	Company	Type	Shares	Δ Shares	Value (USD)	% Δ Value	Held (qtrs)	Est. cost/share	% of Portfolio
ASND	Ascendis Pharma A/S Healthcare	Held	10,281,496	0	$2,742,280,613	+16.6%	26+	before history	23.83%
PBLS	Parabilis Medicines, Inc. Healthcare	NEW	28,933,371	NEW	$791,906,364	NEW	1	unpriced	6.88%
RYTM	Rhythm Pharmaceuticals, Inc. Healthcare	Held	6,666,837	0	$740,218,912	+27.7%	26+	before history	6.43%
PCVX	Vaxcyte, Inc. Healthcare	Held	11,474,599	0	$667,018,439	+0.0%	25	unpriced	5.80%
SION	Sionna Therapeutics, Inc. Healthcare	Held	9,905,045	0	$435,722,929	+9.7%	6	$16.34	3.79%
TYRA	Tyra Biosciences, Inc. Healthcare	Held	12,198,625	0	$389,624,082	−16.6%	20	unpriced	3.39%
EWTX	Edgewise Therapeutics, Inc. Healthcare	Reduced	8,392,730	-2,035,707	$340,996,619	+3.8%	10	$15.67	2.96%
NAMS	NewAmsterdam Pharma Co N.V. Healthcare	Held	9,550,191	0	$323,655,972	+5.9%	15	$14.02	2.81%
COAG	Hemab Therapeutics Holdings, Inc. Healthcare	NEW	7,808,627	NEW	$286,810,869	NEW	1	$27.59	2.49%
SEPN	Septerna, Inc. Healthcare	Held	6,995,858	0	$234,291,284	+39.4%	7	$23.65	2.04%
BCAX	Bicara Therapeutics Inc. Healthcare	Held	7,255,993	0	$215,430,432	+49.3%	8	unpriced	1.87%
MLYS	Mineralys Therapeutics, Inc. Healthcare	Held	7,692,750	0	$207,550,395	−0.4%	14	$16.29	1.80%
GHRS	GH Research PLC Healthcare	Reduced	7,636,813	-39,884	$205,277,533	+90.2%	21	unpriced	1.78%
IRON	Disc Medicine, Inc. Healthcare	Held	2,450,221	0	$179,209,163	+14.4%	6	$62.98	1.56%
SGP	SpyGlass Pharma, Inc. Healthcare	Held	8,021,117	0	$178,550,064	−14.1%	2	$26.90	1.55%
ARTV	Artiva Biotherapeutics, Inc. Healthcare	Added	17,955,642	+8,102,340	$174,169,727	+174.5%	8	$10.47	1.51%
JANX	Janux Therapeutics, Inc. Healthcare	Held	11,189,693	0	$171,873,684	+10.5%	21	unpriced	1.49%
TSHA	Taysha Gene Therapies, Inc. Healthcare	Held	23,555,648	0	$160,413,962	+52.3%	12	$2.03	1.39%
BCRX	Biocryst Pharmaceuticals Inc Healthcare	Held	15,827,186	0	$158,271,860	+5.0%	3	$7.23	1.38%
WVE	Wave Life Sciences, Inc. Healthcare	Held	26,975,505	0	$156,727,684	−19.9%	26+	before history	1.36%
		Reduced	1,246,456	-1,287,689	$153,937,316	−40.7%	4	unpriced	1.34%
ABVX	Abivax S.A. Healthcare	NEW	1,132,557	NEW	$150,924,545	NEW	1	$113.18	1.31%
ORKA	Oruka Therapeutics, Inc. Healthcare	NEW	1,554,597	NEW	$147,950,996	NEW	1	$66.63	1.29%
CLYM	Climb Bio, Inc. Healthcare	Held	11,300,939	0	$147,364,243	+90.4%	20	$12.51	1.28%
SLDB	Solid Biosciences Inc. Healthcare	Added	12,036,126	+2,696,148	$120,240,898	+78.8%	26+	before history	1.04%
ZLAB	Zai Lab Ltd Healthcare	Added	5,743,533	+36,271	$109,127,127	+1.7%	2	$18.54	0.95%
SPRY	ARS Pharmaceuticals, Inc. Healthcare	Held	10,860,977	0	$86,996,425	−0.2%	15	$6.66	0.76%
XNCR	Xencor Inc Healthcare	Added	5,274,274	+377,037	$84,915,811	+43.8%	2	$12.42	0.74%
JBIO	Jade Biosciences, Inc. Healthcare	Held	3,671,083	0	$81,571,464	+58.1%	5	unpriced	0.71%
NTLA	Intellia Therapeutics, Inc. Healthcare	NEW	4,526,926	NEW	$76,595,587	NEW	1	$14.00	0.67%
LBRX	Lb Pharmaceuticals Inc Healthcare	Held	2,208,604	0	$71,680,242	+31.6%	4	unpriced	0.62%
DFTX	Definium Therapeutics, Inc. Healthcare	NEW	1,500,000	NEW	$70,560,000	NEW	1	$24.71	0.61%
ACRS	Aclaris Therapeutics, Inc. Healthcare	Added	12,723,026	+5,918,954	$67,304,807	+163.8%	2	$3.88	0.58%
FDMT	4D Molecular Therapeutics, Inc. Healthcare	Held	5,049,779	0	$67,162,060	+42.9%	13	$17.57	0.58%
SANA	Sana Biotechnology, Inc. Healthcare	NEW	18,750,000	NEW	$65,437,500	NEW	1	$3.22	0.57%
DMRA	Damora Therapeutics, Inc. Healthcare	Added	2,399,702	+392	$62,416,249	+0.4%	2	$25.70	0.54%
MNPR	Monopar Therapeutics Healthcare	Held	667,207	0	$61,776,696	+69.0%	7	$31.96	0.54%
ABOS	Acumen Pharmaceuticals, Inc. Healthcare	Held	20,992,669	0	$56,050,426	+13.1%	20	$10.00	0.49%
GERN	Geron Corp Healthcare	Reduced	42,809,751	-20,961,615	$54,796,481	−42.3%	25	$2.37	0.48%
RZLT	Rezolute, Inc. Healthcare	Added	9,445,039	+265,039	$49,114,202	+75.4%	3	$7.72	0.43%
EVMN	Evommune, Inc. Healthcare	Held	3,494,638	0	$46,443,739	−42.2%	3	$18.82	0.40%
VOR	Vor Biopharma Inc. Healthcare	Reduced	2,402,095	-3,002,903	$44,222,568	−54.1%	22	$112.07	0.38%
IPSC	Century Therapeutics, Inc. Healthcare	Held	17,754,430	0	$43,498,353	+8.4%	2	$2.10	0.38%
AKTS	Aktis Oncology, Inc. Healthcare	Reduced	1,314,405	-188,679	$42,363,273	+57.5%	2	$19.42	0.37%
BIOA	BioAge Labs, Inc. Healthcare	Added	1,671,648	+21,000	$40,972,092	+41.9%	2	$19.24	0.36%
CCCC	C4 Therapeutics, Inc. Healthcare	Held	8,000,000	0	$37,360,000	+77.6%	3	$2.37	0.32%
MIRM	Mirum Pharmaceuticals, Inc. Healthcare	Held	318,554	0	$37,293,116	+26.7%	2	$94.07	0.32%
CAPR	Capricor Therapeutics, Inc. Healthcare	Held	1,507,844	0	$36,308,883	−20.8%	3	$13.06	0.32%
PEPG	PepGen Inc. Healthcare	Held	20,064,545	0	$36,116,181	+1.7%	17	$6.78	0.31%
PRLD	Prelude Therapeutics Inc Healthcare	NEW	6,475,882	NEW	$34,516,451	NEW	1	$4.35	0.30%

Showing the top 50 of 84 positions. Create a free account to see every position, past quarters, search, filters and CSV export.

Covers the securities this platform tracks: U.S.-listed common stock and the put/call positions reported on it. A 13F can also report security types outside that coverage — preferred shares, bonds, warrants, untracked share classes — so the filing's own declared total can exceed the figures above. The source filing is linked at the top of this table.